The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand

Purpose: To investigate the incidence of chemotherapy-induced neutropenia and febrile neutropenia (FN) among patients with gynecologic cancer receiving initial chemotherapy and to determine associated risk factors related to neutropenia and FN. Materials and Methods: This retrospective study gathered the available record data of gynecologic cancer patients who received first-line chemotherapy from January 2012 to December 2015 at Siriraj Hospital,Thailand. All gynecologic cancer patients over the age of 18 and who had received initial chemotherapy were included. Results: Four hundred seven gynecologic cancer patients were included and there were 2,249 cycles of chemotherapy (17 regimens). Two hundred nine patients (52.0%) had severe neutropenia and 11 patients (2.7%) of 407 patients (2.7%) were diagnosed as FN. Carboplatin-containing regimens were the only one risk factor for severe neutropenia in the logistic analysis. Meanwhile, the use of myeloid growth factors for the prevention of FN could reduce the risk of FN (odd ratios 0.03; 95% confidence interval 0.005-0.231). Conclusion: The incidences of severe neutropenia and FN were 52.0% and 2.7%, respectively. It was also shown that myeloid growth factor use might act as a prevention among patient with intermediate risks of FN using cisplatin and doxorubicin.

Febrile neutropenia; Severe neutropenia; Gynecologic cancer; Incidence; Risk factors.

[1] Limvorapitak W., Khawcharoenporn T.: “Incidence, Risk Factors, and Outcomes of Febrile Neutropenia in Thai Hematologic Malignancy Patients Receiving Chemotherapy: A 6-year Retrospective Cohort Study”. Asian Pac J Cancer Prev., 2015, 16, 5945.

[2] Keng M.K., Sekeres M.A.: “Febrile neutropenia in hematologic malignancies”. Curr. Hematol. Malig. Rep., 2013, 8, 370.

[3] Hashiguchi Y., Kasai M., Fukuda T., Ichimura T., Yasui T., Sumi T.: “Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy”. Anticancer Drugs, 2015, 26, 1054.

[4] Lyman G.H., Lyman C.H., Agboola O.: “Risk models for predicting chemotherapy-induced neutropenia”. Oncologist, 2005, 10, 427.

[5] Smith T.J., Bohlke K., Lyman G.H., Carson K.R., Crawford J., Cross S.J., et al.: “Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update”. J. Clin. Oncol., 2015, 33, 3199.

[6] National Comprehensive Cancer Network.: “Myeloid growth factors (version 1.2016)”. 2016.

[7] Aapro M.S., Bohlius J., Cameron D.A., Dal Lago L., Donnelly J.P., Kearney N., et al.: “2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours:. Eur. J. Cancer, 2011, 47, 8.

[8] National Comprehensive Cancer Network.: “Ovarian cancer including fallopian tube cancer and primary peritoneal cancer (version 2.2015)”. 2015.

[9] Jacob L.A., Lakshmaiah K.C., Govindbabu K., Suresh T.M., Lokanatha D., Sinha M., Vijaykumar B.R., Sumathi B.G., Jayashree R.S.: “Clinical and microbiological profile of febrile neutropenia in solid tumors and hematological malignancies at a tertiary cancer care center in South India”. Indian J. Cancer, 2014, 51, 464.

[10] Weycker D., Li X., Edelsberg J., Barron R., Kartashov A., Xu H., Lyman G.H.: “Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors”. J. Oncol. Pract., 2015, 11, 47.